No charge for Four Arts members
Biomarkers are key to helping identify the right patients for the right therapies at the right time while also accelerating the development of new treatments. Dr. Anthony “Nino” Sireci, Senior Vice President of Clinical Biomarkers, Laboratories and Diagnostics at Eli Lilly and Company, will discuss how advances in biomarkers, including blood-based tests, are transforming Alzheimer’s research and care. Drawing on lessons from oncology, he will explore how these innovations are helping pave the way for more targeted treatments and better outcomes for patients, ultimately moving us toward the gold standard of precision medicine for Alzheimer’s disease.
More than 7 million Americans are living with Alzheimer’s. This series brings leading investigators to Palm Beach to share advances in research, from early detection and emerging therapies to the science of prevention. Moderated by Laura Nisenbaum, Ph.D., Interim Chief Science Officer of the ADDF the conversations will be held at the Norton Museum of Art in West Palm Beach and the Dixon Education Building at The Society of the Four Arts. Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to rapidly accelerating the development of novel therapeutics and biomarkers to prevent, treat, and cure Alzheimer’s disease and related dementias.
Presented by the Alzheimer’s Drug Discovery Foundation and The Society of the Four Arts
This lecture series was founded in partnership with Heidi and Tom McWilliams
